Skip to search formSkip to main contentSkip to account menu

Zalypsis

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

PM 00104

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (vol 31, pg 623, 2013)
2013
2013
Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors
2012
2012
Abstract 5587: Phase I study of PM00104 in combination with carboplatin in patients (pts) with advanced solid tumors
Background: PM00104 (Zalypsis ® ) is a synthetic alkaloid related to Jorumycin with a strong antitumor activity against a wide… 
2010
2010
evelopment of an in vitro model for the simultaneous study of the efficacy and ematotoxicity of antileukemic compounds
Hematopoietic system displays a wide spectrum of cell populations hierarchically organized in the bone marrow. Homeostasis in… 
2006
2006
Toxicokinetic evaluation of a novel anti-tumor agent, Zalypsis® (PM00104), in dogs
3095 Zalypsis® (PM00104) is a new synthetic alkaloid related to Jorumycin and Renieramycins. Preliminary insights into the…